Telemedical Devices in the Management of Type 2 Diabetes Mellitus to Improve Diabetic Control and Quality of Life

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Effect on Glucose Control and Quality of Life for People With Type 2 Diabetes of Using a Device to Measure Glucose Levels at Home and Send Them to the Clinic, Rather Than Attending an Out-patient Clinic for Blood Tests

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04038528
• Other study ID #: 2018-DC-2-0
• Status: Active, not recruiting
• Start date: March 1, 2018
• Est. completion date: July 31, 2020

Study information

• Verified date: July 2019
• Source: Centro Studi Internazionali, Italy
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to understand, in adult patients with Type 2 diabetes mellitus, if the use of telemedicine (monitoring and treatment without patients having to attend a healthcare facility) and home-based care is more effective than traditional general practitioner (GP) and outpatient care in terms of patients taking medication regularly and their quality of life.

The hypothesis of this study is that patients with Type 2 diabetes mellitus uploading data on a telemedicine system achieve a glycemic control, evaluated in terms of glycated hemoglobin levels, similar to that of patients followed in a traditional diabetes outpatient department, with improvements to quality of life

Description:

Background and study aims Diabetes mellitus is a long-lasting disease in which the level of blood sugar is higher than normal. High level of sugar in the blood can lead to serious consequences, including blindness, kidney failure, amputation of limbs, coma and death. Patients with diabetes need to regularly take their medicine and to make sure they monitor the level of sugar in their blood on daily basis. This can affect their quality of life. The aim of this study is to understand if telemedicine (monitoring and treatment without patients having to attend a healthcare facility) and home-based care is more effective than traditional GP and outpatient care in terms of patients taking medication regularly and their quality of life.

Who can participate? Men and women who live in the study area, have been diagnosed with type 2 diabetes at least 1 year before the start of the study and have been on the same treatment for at least 3 months.

What does the study involve? The participants will be recruited by GPs and doctors working in diabetes centres. Participants will be randomly assigned to one of two groups. One group will be treated and followed according as usual. They will test their blood sugar level at home and record it on paper. They will attend a diabetes outpatient clinic for follow-up. The other group will record the level of blood sugar using a digital home-based system that will send data to the diabetes clinic for follow-up. All participants will receive treatment as appropriate from the clinic. At the end of the study (after 18 months), the two groups will be compared to assess which group achieved a better control of their blood sugar level and which experienced a better quality of life, assessed using a questionnaire. The participants will also have their height, weight, waist circumference, blood pressure, cholesterol and blood fats measured at the beginning and end of the study.

What are the possible benefits and risks of participating? All patients will receive medication as usual and the control group will continue to attend outpatient clinic, so there are no additional risks associated with participating in the trial. The telemedicine group might benefit from avoiding the inconvenience of having to attend outpatient clinics and from a more rapid response to changes in their blood sugar level from the clinic.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 350
• Est. completion date: July 31, 2020
• Est. primary completion date: March 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with type 2 diabetes mellitus (T2DM)

2. Diagnosis of DM made at least 1 year before the start of the study

3. Hypoglycemic treatment remained the same in the 3 months preceding the start of the study

Exclusion Criteria:

1. Diabetes other than T2DM

2. Pregnant women

3. Chronic conditions other than T2DM

4. Unable to give informed consent

5. Dementia or psychiatric conditions that can affect a person's will or ability to participate in the study

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Behavioral:
• telemonitoring of T2DM
Baseline record of: Weight Height BMI Abdominal circumference Winsor Index ECG Retinography Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups. Telemedicine group (intervention): Blood sugar (two measurements per week). Body weight (weekly) Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed Control group (control): Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications. Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter

Locations

Country	Name	City	State
Italy	ASP Catanzaro	Catanzaro

Sponsors (2)

Lead Sponsor	Collaborator
Centro Studi Internazionali, Italy	GPI SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	glycated hemoglobin (GlyH) level	Level of glycated hemoglobin (GlyH) at the end of the study (18 months) in patients followed with telemedicine and in the control group when compared to baseline, with normal GlyH defined as <5.6%.	18 months
Secondary	Quality of life perception	Quality of life as perceived by the patients measured using the SF-36 questionnaire at baseline, 6 months and at the end of the study (18 months)	18 months
Secondary	Body mass index (BMI)	BMI calculated from height and weight at baseline and at the end of the study	18 months
Secondary	Abdominal circumference	Difference in the abdominal circumference measured at baseline and at the end of the study	18 months
Secondary	Triglyceride	Blood triglyceride level at baseline and at the end of the study	18 months
Secondary	LDL-cholesterol	Blood LDL-cholesterol level at baseline and at the end of the study	18 months
Secondary	Systolic Blood Pressure (BP)	Systolic BP at baseline and at the end of the study	18 months
Secondary	Diastolic BP	Diastolic blood pressure at baseline and at the end of the study	18 months
Secondary	Compliance	Compliance with blood glucose testing (number of actual measurements/expected number of measurements in the whole timeframe of the study), with participants divided into four groups: poor (<50%), mediocre (50-70%), good (70-90%), optimal (90-100%)	18 months
Secondary	Hyperglycemic events	Number of hyperglycemic events during the timeframe of the testing, defined as a spot measure of fasting blood sugar >300 mg/dl	18 months